Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 416 • 2013 ACR/ARHP Annual Meeting
Changes In Body Composition On Two Different Glucocorticoid Regimens In Early RA: Experience From The Cobra-Light Trial
Nicole P.C. Konijn¹, Karin Britsemmer², Marieke M. ter Wee¹, Debby den Uyl¹, Birgit S. Blomjous¹, Maarten Boers^3,4, Dirkjan van Schaardenburg^5,6, Willem F. Lems^1,6 and Michael T Nurmohamed^5,7, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁴Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁵VU University Medical Center, Amsterdam, Netherlands, ⁶Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁷Rheumatology, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands
Background/Purpose: Prednisolone improves joint inflammation and disease severity in rheumatoid arthritis (RA), but is associated with multiple cardiovascular, metabolic and endocrine side effects and may…
Abstract Number: 2296 • 2013 ACR/ARHP Annual Meeting
Are SDAI50 and DAS28 Response Measures Comparable In Early Rheumatoid Arthritis Patients?
Mohammed Omair¹, Edward C. Keystone², Juan Xiong³, Gilles Boire⁴, Janet E. Pope⁵, J. Carter Thorne⁶, Carol A. Hitchon⁷, Boulos Haraoui⁸, Diane Tin⁹, Deborah Weber³, Vivian P. Bykerk² and Pooneh Akhavan², ¹Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ²Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵St Joseph Health Care, London, ON, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁸Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: An essential element of treat to target strategy is adjusting therapy in the absence of achieving a target response by 12 wk. A DDAS28…
Abstract Number: 1368 • 2013 ACR/ARHP Annual Meeting
The Effect Of Vitamin D On Early Rheumatoid Arthritis: A Retrospective Cohort Analysis
Faye A H Cooles¹, Arthur G Pratt^2,3,4, Wan-Fai Ng^3,5, Terry J Aspray³ and John D Isaacs², ¹Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ³Musculoskeletal Directorate, The Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁵Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom
Background/Purpose: There is increasing evidence that vitamin D has immunoregulatory properties in autoimmunity. In established rheumatoid arthritis (RA) there appears to be an inverse association…
Abstract Number: 329 • 2013 ACR/ARHP Annual Meeting
Health-Related Quality Of Life In Early Psoriatic Arthritis In Comparison With Early Rheumatoid Arthritis. A 5-Year Follow-Up Report From The Swedish Early Psoriatic Arthritis Registry and The Swedish Early Intervention In RA Registry
Lars Törnqvist¹, Tomas Husmark², Ulla R. C. Lindqvist³, Gerd-Marie Alenius⁴, Per Larsson⁵, Annika Teleman⁶, Mats Geijer⁷, Lars Erik Kristensen⁸, Ingrid Thyberg⁹ and Elke Theander¹⁰, ¹Department of Rheumatology, Skåne University Hospital Malmö, Lund University, Sweden, Malmö, Sweden, ²Department of Rheumatology, Falu Hospital, Falun, Sweden, ³Department of Medical Sciences, Rheumatology, University Hospital, Uppsala university, Uppsala, Sweden, ⁴Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁵Dept of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁶Department of Rheumatology, Spenshult Hospital, Oskarstrom, Sweden, ⁷Skåne University Hospital, Lund, Center for Medical Imaging and Physiology, Lund, Sweden, ⁸Rheumatology, Skåen University Hospital, Lund University, Lund, Sweden, ⁹Rheumatology, Linköping University Hospital, Linkoping, Sweden, ¹⁰Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Studies on early psoriatic arthritis (ePsA) are still rare and data on health related quality of life (HRQoL) in ePsA are lacking completely. To…
Abstract Number: 2270 • 2013 ACR/ARHP Annual Meeting
US Guided Treat-To-Target Approach In Early RA: Implications For Uncoupling Of Disease Activity and Structural Damage
Yasser El Miedany¹, Maha El Gaafary², Sally Youssef³ and Annie Nasr⁴, ¹Rheumatology, Medway Hospital, Gillingham, United Kingdom, ²Community, Environmental and Occupational Medicine, Ain Shams University, Cairo, Egypt, ³Rheumatology & Rehabilitation, Ain Shams University, Cairo, Egypt, ⁴Radiology, Ain Shams University, Cairo, Egypt
Background/Purpose: To assess the relationship between inflammation and joint destruction in RA patients who have not responded clinically to treatment using Musculoskeletal US as a…
Abstract Number: 1343 • 2013 ACR/ARHP Annual Meeting
Are There Differences Between Young and Older Onset Early Rheumatoid Arthritis and Does This Impact Outcomes? An Analysis From The Canadian Early Arthritis Cohort
Michael Arnold¹, Vivian P. Bykerk², Gilles Boire³, Boulos Haraoui⁴, Carol A. Hitchon⁵, J. Carter Thorne⁶, Edward Keystone⁷ and Janet E. Pope⁸, ¹Medicine/Rheumatology, University College Dublin, Ireland, Dublin, Ireland, ²Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁵Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ⁸Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: To determine the impact of age on disease and remission in early rheumatoid arthritis (ERA). Methods: Data from the Canadian Early Arthritis Cohort (CATCH)…
Abstract Number: L14 • 2013 ACR/ARHP Annual Meeting
For Remission Induction with Glucocorticoid Bridging, Methotrexate Monotherapy Is As Effective As a Combination with Other Dmards, with Fewer Reported Side Effects: 4 Month Primary Outcome of Carera, a Randomized Induction Strategy and Treat to Target Trial in Early RA
Diederik De Cock¹, Sabrina Meyfroidt¹, Johan Joly², Kristien Van der Elst^2,3, Rene Westhovens^4,5 and Patrick Verschueren^2,6, ¹Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, ²University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ³Skeletal Biology and Engineering Research Center, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium, ⁴University of Leuven, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration; Rheumatology, University Hospital Leuven, Leuven, Belgium, ⁵Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, KU Leuven, Leuven, Belgium, ⁶1Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium
Background/Purpose: Intensive combination therapy with glucocorticoids (GCs) is the most favorable treatment to benefit from the window of opportunity in early Rheumatoid Arthritis (eRA) but…
Abstract Number: 2275 • 2013 ACR/ARHP Annual Meeting
Responsiveness Of The Outcomes Measures In Rheumatology Clinical Trials Initiative’s Preliminary Flare Questions To Detect Flares Within Patients In The Canadian Early Arthritis Cohort
Vivian P. Bykerk^1,2, Karen Visser³, Ernest Choy⁴, Clifton O. Bingham III⁵, Daming Lin², Juan Xiong⁶, Gilles Boire⁷, Boulos Haraoui⁸, Carol A. Hitchon⁹, Janet E. Pope¹⁰, J. Carter Thorne¹¹, Diane Tin¹², Edward C. Keystone¹³, Susan J. Bartlett¹⁴, - CATCH Investigators¹⁵ and - OMERACT Flare Working Group¹⁶, ¹Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, ⁵Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹⁰St Joseph Health Care, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹³Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁴Clinical Epidemiology, McGill University, Montreal, QC, Canada, ¹⁵Canadian Collaboration, Toronto, ON, Canada, ¹⁶International Collaboration, Baltimore, MD
Background/Purpose: OMERACT (OM) recently developed preliminary flare questions (PFQs) that capture domains important to patients (pts) to identify a flare of RA1. Whether these change…
Abstract Number: 1329 • 2013 ACR/ARHP Annual Meeting
Physician Global Assessment At Three Months Is Strongly Predictive Of Remission At 12 Months In Early Rheumatoid Arthritis. Results From The Canadian Early Arthritis Cohort
Tommy Choy¹, Vivian P. Bykerk², Gilles Boire³, Boulos Haraoui⁴, Carol A. Hitchon⁵, J. Carter Thorne⁶, Edward C. Keystone⁷ and Janet E. Pope⁸, ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁵Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: To determine predictors of 1-year remission in early rheumatoid arthritis (ERA) using baseline and 3 months data. Methods: The Canadian Early Arthritis Cohort (CATCH)…
Abstract Number: 2257 • 2013 ACR/ARHP Annual Meeting
Symptom Complexes At The Beginning Of Rheumatoid Arthritis: A Qualitative Exploration In At Risk Individuals and In New Patients Prior To Diagnosis
Rebecca J Stack¹, Lilian H.D. van Tuyl², Maurits Sloots³, Lotte A. van de Stadt³, Wijnanda Hoogland³, Bertha Matt³, Christian D Mallen⁴, Rumandeep Tiwana¹, Karim Raza¹ and Dirkjan van Schaardenburg³, ¹Centre for Translational Inflammation Research, University of Birmingham, Birmingham, United Kingdom, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁴Arthritis Research UK Primary Care Centre, University of Keele, Keele, United Kingdom
Background/Purpose: To achieve better prediction of the development of rheumatoid arthritis (RA) a EULAR study group recommended identification and assessment of symptoms in those with…
Abstract Number: 1304 • 2013 ACR/ARHP Annual Meeting
Anti-Carbamylated Antibody Positivity Is Associated With More Severe Radiological Progression In Patients With Recent Onset ACPA Negative Rheumatoid Arthritis: Results From The Norfolk Arthritis Register (NOAR)
Jenny H. Humphreys¹, Suzanne M. Verstappen¹, Kimme L. Hyrich², Tarnya Marshall³, Anne Barton^4,5, René E.M. Toes⁶, Leendert A. Trouw⁶ and Deborah P. Symmons^4,7, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁵NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Autoantibodies against carbamylated proteins (anti-CarP) have been associated with more severe radiological damage in patients with rheumatoid arthritis (RA), including in a small subgroup…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].